Enhanced cardiac late Na current (late I Na ) and increased sarcoplasmic reticulum (SR)-Ca 2+ -leak are both highly arrhythmogenic. This study seeks to identify signalling pathways interconnecting late I Na and SR-Ca 2+ -leak in atrial cardiomyocytes (CMs).
Introduction
The late Na + current (late I Na ) is a small Na + inward current, which follows the peak Na + current, persists throughout the action potential 1 and plays a small electrophysiological role under physiological conditions. However, an enhanced late I Na significantly contributes to total Na + influx. 2 Late I Na was shown to be increased in ischemia 3 and oxidative stress 4 as well as in heart failure 5 and atrial fibrillation (AF). 6 Under these conditions, the total amount of Na + entering the cell via late I Na can even exceed that of peak I Na . 7 In addition, an increased late I Na prolongs action potential duration (APD) 8 and promotes early afterdepolarizations (EADs). 9 EADs and triggered atrial activity constitute a pathomechanism for the initiation and perpetuation of AF. 10 Another relevant mechanism in AF is an increased SR-Ca 2+ -leak, 11 which occurs when altered ryanodine receptor type-2 (RyR2) spontaneously opens in diastole releasing small amounts of Ca 2+ (Ca 2+ sparks). The increased diastolic Ca 2+ leak in AF is caused by CaMKII-dependent hyperphosphorylation of RyR2, which triggers delayed afterdepolarizations (DADs) via activation of the Na + /Ca 2+ exchanger (NCX) leading to transient inward currents (I ti ). 12 Furthermore, it has been suggested that PKA-dependent phosphorylation of RyR2 decreases the amount of RyR2-bound calstabin-2 and also contributes to the instability of RyR2. 13 Thus, both arrhythmic triggers (increased late I Na and increased SR-Ca 2+ -leak) coexist in AF. This study investigates if both cellular phenomena are linked and elucidates the underlying pathways.
Methods

Human myocardial tissue
All procedures performed conform to the Declaration of Helsinki and were approved by the local ethics committee. Written informed consent was received from all participants prior to inclusion. Human atrial myocardium was obtained from resections of the left atrial appendage during open heart surgery. The samples were immediately placed in cooled cardioplegic solution (in mmol/L: NaCl 110, KCl 16, MgCl 2 16, NaHCO 3 16, CaCl 2 1.2, and glucose 11) and kept cool until cell isolation started or instantly frozen in liquid nitrogen and stored at 2808C for western blot analysis.
Myocyte isolation 2.2.1 Mouse
The animal study was approved by the local or ethics review board and procedures were performed in accordance with the NIH guidelines (guide for the care and use of laboratory animals) and the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. Mice were killed in isoflurane 133 anaesthesia (5%) by cervical dislocation. To ensure sufficient digestion of atrial myocardium, mice were administered 100 IU heparin by an intraperitoneal injection prior to isolation. A Langendorff apparatus was used to retrogradely perfuse the explanted hearts with an initially Ca 2+ -free solution containing (in mmol/L) NaCl 3 10, HEPES 10, Taurine 30, 2,3-butanedione monoxime (BDM) 10, glucose 5.5, and phenol red 0.032 (378C, pH 7.4). Then, 7.5 mg/mL of liberase 1 (Roche Diagnostics, Mannheim, Germany) and trypsin 0.6% (Life Technologies, Carlsbad, CA, USA) as well as 0.125 mmol/L of CaCl 2 were added to the perfusion solution. Once the tissue became flaccid, ventricular and atrial myocardium was separated by cutting off the atria above the atrioventricular valve level. The atrial myocardium was cut into small pieces and again dispersed in solution. Concentration of Ca 2+ was stepwise increased every 7 min until desired concentration was reached. Cells were plated on laminin-coated recording chambers and left for 20 min to enable settling.
Human
Left atrial myocardium was rinsed, cut into small pieces and incubated at 378C in a spinner flask filled with Ca 2+ -free solution containing In all experiments, myocytes were mounted on the stage of a microscope (Nikon T 300). Fast capacitance was compensated in cell-attached configuration. Membrane capacitance and series resistance were compensated after patch rupture. Signals were filtered with 2.9 and 10 kHz Bessel filters and recorded with an EPC10 amplifier (HEKA Elektronik). Myocytes were held at 2120 mV and late I Na was elicited using a train of pulses to 235 mV (1000 ms duration, 10 pulses, and basic cycle length 2000 ms). Recordings were started 5 min after rupture. Experiments were conducted at room temperature. The measured current was integrated (between 50 and 100 ms) and normalized to the membrane capacitance. For action potential recordings, ruptured-patch whole-cell voltage-clamp experiments were used to measure membrane potential (current-clamp configuration). For membrane potential measurements, microelectrodes were filled with (in mmol/L) 120 K-aspartate, 8 KCl, 7 NaCl, 1 MgCl 2 , 10 HEPES, and 5 Mg-ATP (pH 7.2, KOH). The bath solution contained (mmol/L) 135 NaCl, 5.4 KCl, 1 MgCl 2 , 1 CaCl 2 , 10 glucose, and 10 HEPES (pH 7.4, NaOH). Action potentials were continuously elicited by square current pulses of 1-2 nA amplitude and 1-5 ms duration at 3 Hz. Access resistance was typically 20 MV after patch rupture. When appropriate, ATX-II (0.5 nmol/L) or ranolazine (10 mmol/L) was added to the bath solution. Fast capacitance was compensated in cell-attached configuration. Membrane capacitance and series resistance were compensated after patch rupture. Signals were filtered with 2.9 and 10 kHz Bessel filters and recorded with an EPC10 amplifier (HEKA Elektronik). Recordings were started 5 min after rupture. All experiments were conducted at room temperature. 
Intracellular
Human
Isolated CMs were stained and measured as annotated above with the following differences: Fluo 3 AM loading buffer either contained Ranolazine CMs were isolated and plated as described above and incubated with a Fluo-4 AM loading buffer (10 mmol/L, Molecular Probes) for 15 min. In the intervention groups, the loading buffer also contained the respective active agents as described above for mouse/human confocal microscopic measurements. After staining, the CMs were superfused with experimental solution (as described in the section 'Confocal microscopy') for 5 min before measurements were started to enable complete de-esterification of intracellular Fluo-4 and allow cellular rebalance of Ca 2+ cycling properties.
During measurements, CMs were continuously superfused with experimental solution. Measurements were performed with a Nikon Eclipse TE2000-U microscope provided with a fluorescence detection system (ION OPTIX Corp. 
Western blots
Mouse hearts were rapidly removed and immersed in oxygenated KrebsHenseleit buffer (in mmol/L: NaCl 118, KCl 4.8, KH 2 PO 4 1.2, CaCl 2 2.5, MgSO 4 1.2, pyruvic acid 2, glucose 5.5, Na 2 EDTA 0.5, and NaHCO 3 25, pH 7.4). Mouse right atria were quickly excised and suspended in a chamber of the Danish Myo Technologies (DMT) myograph containing 8 mL of oxygenated Krebs-Henseleit buffer at 378C. The spontaneously beating right atria were preincubated with late Na + current, CaMKII, or PKA inhibitors for 30 min, and then incubated with 0.5 nmol/L of ATX-II for an additional 30 min. The atria were then snap-frozen in liquid nitrogen and stored at 2808C. Atria were lysed with Tissue Lyser (Qiagen, Valencia, CA, USA) in 0.2 mL of lysis buffer containing 20 mmol/L of Tris, pH 7.5, 2 mmol/L of EDTA, 10 mmol/L of EGTA, 0.25 mmol/L of sucrose, 1% Triton X-100, and 1 tablet of protease inhibitor/10 mL (Sigma, St Louis, MO, USA). Lysates were incubated on ice for 20 min and then centrifuged at 9408 g for 5 min at 48C. The supernatant was saved. About 20 mg of protein was loaded with SDS sample buffer, run on a 10% SDS -PAGE, transferred, and probed for phospho-CaMKII at threonine 287 and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-phospholamban (PLN) at threonine 16, phospho-PLN at threonine 17, phospho-RyR2 at serine 2808, and phospho-RyR2 at serine 2814 (Badrilla, Leeds, UK). Secondary antibody was horseradish peroxidase-linked goat anti-rabbit (1 : 1000; PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). The intensity of individual bands from western blots was quantified using ImageJ software, normalized to GAPDH, and then shown relative to the control group value.
FRET measurements and data analysis
Freshly isolated adult mouse atrial CMs from EPAC1-camps mice were plated onto laminin-coated coverslides and allowed to settle for 30 min. Subsequently, coverslides with isolated CMs were mounted in an imaging chamber (Attofluor cell chamber, Invitrogen) equipped with an electrode. ATX-II (0.5 nmol/L) was added to the imaging chamber 50 s after the start of the measurements, and 100 nmol/L of isoprenaline was added after the ATX-II reaction reached a stable plateau, usually after 5 min. FRET data analysis was performed using the Origin 8.5 software as previously described.
To calculate the corrected FRET ratio, we subtracted the bleedthrough of the donor fluorescence (CFP) into the acceptor (YFP) channel using the equation: FRET ratio ¼ (YFP 2 0.63 × CFP)/CFP, where 0.63 is a bleedthrough coefficient measured in cells expressing CFP only and normalized the values to the initial FRET ratio recorded at the beginning of every experiment. These data are presented as YFP/CFP ratio (norm.) in the results.
Statistical analysis
All data are presented as mean + SEM. Student's t-test was used except for Figures 1D and 7D (two-way ANOVA with the Bonferroni post hoc test). Values with P , 0.05 were considered as statistically significant.
Results
Effects of late I Na modulation and CaMKII inhibition on SR-Ca 21 -leak
Atrial CMs isolated from hearts of wild-type (WT) mice were treated with Anemonia sulcata toxin II (ATX-II, 0.5 nmol/L), which led to an increase of the late I Na integral by 53 + 16% compared with untreated control (patch-clamp P , 0.05, Figure 1 A and B) . The duration of the action potential (APD90) was prolonged by 1.8-fold by ATX-II (APD90 ATX-II vs. control ¼ 104 + 15 vs. 56 + 6 ms, Figure 1C and D, P , 0.001). This effect could be antagonized by additional treatment with the late I Na inhibitor Ranolazine (10 mmol/L; Figure 1C and D). Figure 2A and B, P , 0.001). In addition, the amplitude of Ca 2+ sparks was increased upon ATX-II treatment by 7 + 1%
( Figure 1C , P , 0.001) and the size of detected Ca 2+ sparks was also increased (data not shown). Conclusively, the resulting calculated SR-Ca 2+ -leak (CaSpF × Ca 2+ spark duration × width × amplitude) was increased 2.4-fold ( Figure 2D , P , 0.001). Accordingly, inhibition of late I Na with Ranolazine (10 mmol/L) prevented the ATX-II-induced increase in CaSpF ( Figure 2B , ATX-II + Ran vs. ATX-II, P , 0.01) and SR-Ca 2+ -leak ( Figure 2D , reduced by 49 + 10% compared with ATX-II alone, P , 0.01). To exclude unspecific actions of Ranolazine, we additionally used the Na Figure 4D , P , 0.05 each). PKA inhibition additionally reduced the amplitude of detected Ca 2+ sparks ( Figure 4C , P , 0.05).
Effects of late I Na augmentation on intracellular cAMP levels
As PKA is activated by cAMP, we measured cytoplasmic cAMP levels upon ATX-II treatment in atrial CMs of EPAC-camps transgenic mice. 14 Indeed, ATX-II (0.5 nmol/L) increased cAMP levels (FRET ratio ATX-II vs. control ¼ 0.96 + 0.0047 vs. 1.0 + 0.007; P , 0.001, Figure 5A and E). This response made up for 28% of the maximal 
Effects of late I Na modulation on phosphorylation of key Ca 21 -handling proteins
To further investigate the roles of CaMKII and PKA, we performed Western blots from extracted right murine atria that had been perfused with ATX-II and the respective inhibitors ( Figure 6 and see Supplementary material online, Figure S1 ). An augmentation of late I Na (ATX-II, 0.5 nmol/L) increased the phosphorylation of CaMKII target sites PLN-T17 and RyR2-S2814 ( Figure 6A and B, P , 0.05 each). In addition, CaMKII autophosphorylation at T287 was increased (P , 0.05). The hyperphosphorylation of CaMKII targets could be prevented by Ran (10 mmol/L), TTX (2 mmol/L), and AIP (1 mmol/L), but not by H89 (5 mmol/L; Figure 6A and B, P , 0.05 each).
Similarly, PKA targets PLN-S16 and RyR2-S2808, were hyperphosphorylated in ATX-II-treated atrial myocardium vs. control (P , 0.05), which could be prevented by treatment with Ranolazine, TTX, or H89, but not with AIP ( Figure 6A and B, P , 0.05 each). Figures 2D and 7B and C ) . This hypothesis was confirmed in CaMKII-knockout mice. Here, the treatment with ATX-II also increased SR-Ca 2+ load (by 37 + 9%, Figure 7G and H, P , 0.05). In contrast, the inhibition of PKA (ATX + H89) decreased Interestingly, ATX-II treatment did not significantly alter k sys 2 k caff ( Figure 7E , P ¼ 0.15). Additional inhibition of CaMKII, however, yielded an acceleration of Ca 2+ reuptake into the SR (k sys 2 k caff ATX + AIP vs.
Effects of late I
control, increased by 34 + 7%; P , 0.05). In contrast, inhibition of PKA decelerated SR reuptake (ATX + H89 vs. control, decreased by 33 + 6%; P , 0.001). Moreover, ATX-II treatment increased the fractional Ca 2+ release ( Figure 7F , ratio F/F 0 /F/F 0 caff, ATX-II vs. control ¼ 0.80 + 0.02 vs. 0.73 + 0.02, P , 0.01), which was counteracted by PKA inhibition but not by CaMKII inhibition ( Figure 7F ).
Effects of late I Na , CaMKII, and PKA inhibition in human AF
In human isolated left atrial CMs from patients with permanent AF (for patient characteristics see Table 1 
Discussion
The present data show for the first time that an enhancement of late I Na potently induces SR-Ca 2+ -leak in atrial CMs due to (i) an activation of CaMKII, which promotes diastolic RyR2 openings by hyperphosphorylation of RyR2 (Ser2814) and (ii) an activation of PKA (stimulation of AC 5/6 and increase of cAMP), which subsequently facilitates SR-Ca 2+ -accumulation by increased phosphorylation of PLN (Ser16). Importantly, both kinases are necessary for late I Na -dependent SR-Ca 2+ -leak induction.
Late I Na potently induces SR-Ca 21 -leak
To our knowledge, no direct measurements of SR-Ca 2+ -leak as a function of late I Na have been performed in atrial CMs. There is evidence in 
5/75). (E) Representative confocal line scans of atrial CM from CaMKIIdc-KO mice. (F) Mean values of the SR-Ca
2+
-leak (n ¼ 5/148 vs. 5/140, P ¼ 0.40). *significant vs. control; # significant vs. ATX-II. * /# P , 0.05; ** /## P , 0.01; *** /### P , 0.001.
Late I Na and SR-Ca 2+ -leak in atrial myocardium Our data additionally show that CaMKII is essential for late I Nadependent SR-Ca 2+ -leak induction as it can be effectively prevented by the specific CaMKII inhibitor AIP and an elevated late I Na failed to increase SR-Ca 2+ -leak in CaMKII-knockout mice. We further used KBR to inhibit the reverse mode of NCX function, 21 which also suppressed SR-Ca 2+ -leak induction. It can thus be assumed that CaMKII is activated by Ca 2+ , which has entered the cell via NCX in the setting of Na + overload. This mechanism may be pronounced in AF where NCX function is increased. 12 Of note, it was shown that CaMKII, in turn, can phosphorylate Na v 1.5, which enhances Na + influx via late I Na . 22 Thus, cytoplasmic ion imbalance may establish a vicious circle in CMs, which maintains CaMKII activation and includes positive feedback on SR-Ca 2+ -leak and late I Na .
Late I Na increases cellular cAMP levels and activates PKA
PKA is also known to regulate RyR2 properties and was suggested to be involved in the disruption of diastolic RyR2 closure found in AF. 13 When PKA was inhibited in the setting of an increased late I Na , we could successfully prevent the induction of SR-Ca 2+ -leak. Thus, activation of PKA seems to be equally essential for the late I Na -dependent induction of the SR-Ca 2+ -leak. Indeed, the western blot data demonstrate that the PKA-specific target sites at PLN (S16) and RyR2 (S2808) are hyperphosphorylated in ATX-II-treated atrial myocardium. The fact that PKA is activated by cytoplasmic Na + influx via late I Na has, to the best of our knowledge, not yet been described-either in atrial or in ventricular CMs-and further corroborates the link between Na + currents and cellular Ca 2+ -cycling properties. Whereas the activation of CaMKII by Na + -induced cellular Ca 2+ overload is rather expected, nothing is known about the mechanism of Na + -dependent PKA activation. PKA is an integral part of the b-adrenergic signalling pathway and is known to be activated by cAMP. We show that an enhancement of late I Na by ATX-II induces a significant decrease of the measured YFP/CFP ratio in EPAC-camps transgenic mice, 14 indicating an increase in cytoplasmic cAMP levels. The change in YFP/CFP ratio during ATX-II-treatment was pronounced as it made up for 28% of the maximal response upon b-adrenergic stimulation and can thus sufficiently explain PKA activation. We further used inhibitors of cardiac PDEs and ACs to elucidate if the late I Na -related increase in cytoplasmic cAMP levels results from an inhibition of cardiac PDEs or an activation of ACs. Interestingly, preincubation with the unspecific PDE inhibitor IBMX did not block the cAMP response upon ATX-II treatment, showing that ATX-II does not exert its effect on cAMP levels by influencing PDE activity. In contrast, pre-inhibition of AC5 and 6 (the major cardiac AC isoforms) with NKY80 15 clearly attenuated the cAMP response upon ATX-II. Thus, the enhanced late I Na by ATX-II increases cytoplasmic cAMP levels by activating ACs. The fact that reverse-mode NCX inhibitor KBR also reduced ATX-II-dependent production of cAMP suggests a Ca 2+ -dependent activation of ACs. 
Late
Limitations of the study
(i) The mouse dataset relies on an induction of late I Na by ATX-II. This toxin has often been used for this purpose, mostly in ventricular CMs, and has been shown to delay Na + channel inactivation and consequently induce Ca 2+ overload. 25, 26 In our current study, ATX-II concentration was titrated to yield an increase of late I Na current in a range that is comparable to the magnitude found in cardiac disease and thus to approximate a previously healthy murine atrial CM to the compromised Na + gating found in human AF. 6 Although the translatability of our results is shown by the fact that inhibition of the respective kinases as well as of late I Na successfully suppresses SR-Ca 2+ -leak in human AF, SR-Ca 2+ -leak, and that both forms of diastolic Ca 2+ -loss are apparently not altered independently in certain cell types and diseases. 29 Further studies investigating the non-spark-related leak in relation to late I Na current and CaMKII/PKA activity may nevertheless be useful. However, Ca 2+ sparks and waves may be of particular relevance as they constitute potent arrhythmogenic triggers. (v) BDM was used during murine cell isolation to increase cell quality and cell yield due to a reduction in actin -myosin interaction and ATP consumption. There are, however, concerns about BDM acting as a chemical phosphatase. As these side effects were shown to be dose-dependent, 30 we used a very low concentration of BDM (10 mmol/L). At this concentration, no significant effects of BDM on protein phosphorylation could be detected. 19 (vi) The use of caffeine in combination with Fluo dyes is an established method but might lead to some quenching of the indicator. This effect should be equally present in all groups and is known to be Ca 2+ -dependent. Therefore, the detected differences in SR-Ca 2+ -load would, if anything, rather be underestimated in this study.
Clinical relevance
Our data support the potentially high antiarrhythmic potency of late I Na inhibition as this approach reduces SR-Ca 2+ -leak in murine and human atrial CMs by interfering with the activity of CaMKII and PKA, both of which are known to exert deleterious effects in human cardiac disease. Inhibition of late I Na appears to be a feasible way to control CaMKII activity in atrial myocardium and may overcome the current lack of cardiac-specific and clinically applicable CaMKII inhibitors. As CaMKII is crucially involved in neuronal processes, a systemic CaMKII inhibition could produce severe neurological side effects. Furthermore, our data show that inhibition of late I Na as a therapeutic approach not only reduces CaMKII activation, but also interferes with the cAMP -PKA system and thus includes effects usually attributed to b-blockers. Of note, Ranolazine is currently being evaluated in clinical trials as a new treatment option for patients with AF (RAFFAELO Trial, EudraCT no.: 2011-002789-18, HARMONY Trial, EudraCT no.: 2011-001134-42) and new, even more selective and potent late I Na inhibitors are currently under both experimental and clinical investigation (e.g. GS-6615; NCT01847391).
Summary
The dataset presented in this study shows that enhancement of late I Na in atrial CM exerts significant effects on Ca 2+ homeostasis. It leads to an NCX-dependent activation of CaMKII and an AC-mediated increase in cytoplasmic cAMP levels with subsequent activation of PKA. This results in hyperphosphorylation of the respective target sites at RyR2 and PLN and triggers a significant increase in SR-Ca 2+ -leak. Importantly, activation of both CaMKII and PKA is necessary for increased SR-Ca 2+ -leak to occur in the atria. Owing to the fact that SR-Ca 2+ -reuptake is simultaneously facilitated, increased SR-Ca 2+ -leak does not alter SR-Ca 2+ -load. Increased SR-Ca 2+ -turnover, however, is potentially highly arrhythmogenic. The increased diastolic SR-Ca 2+ -leak in human AF can effectively be reduced by CaMKII inhibition as well as by inhibition of late I Na .
Supplementary material
Supplementary material is available at Cardiovascular Research online.
